MAZEHealthcare · BiotechnologyMAZE Stock Forecast: Maze Therapeutics, Inc. Price Predictions for 2026-2027
The 12 Wall Street analysts covering Maze Therapeutics, Inc. hold a median 12-month price target of $55 — +101.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 24 of 100 as at 1 Aug 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
MAZE stock analysis: one number for the whole business
Consensus tells you what everyone already believes. The model scores Maze Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (77): Analysts have, on balance, been raising their forecasts.
Growth (8): Sales and profits are flat, shrinking, or growing more slowly than they were.
The rank is the raw material. Whether the rules would actually own Maze Therapeutics, Inc. — and when they’d sell — is the membership.
MAZE stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on MAZE, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +101.2% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 14 Apr 2026 | Truist Securities | Maintains | Buy | $68 → $64 |
| 31 Mar 2026 | JP Morgan | Maintains | Overweight | — |
| 25 Mar 2026 | BTIG | Reiterates | Buy | — |
| 25 Mar 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 18 Mar 2026 | Truist Securities | Initiates | Buy | — |
| 16 Mar 2026 | Wedbush | Maintains | Outperform | — |
| 10 Mar 2026 | Mizuho | Initiates | Outperform | — |
| 9 Mar 2026 | BTIG | Reiterates | Buy | — |
| 4 Mar 2026 | Guggenheim | Maintains | Buy | — |
| 16 Jan 2026 | BTIG | Maintains | Buy | — |
| 4 Dec 2025 | Wells Fargo | Initiates | Overweight | — |
| 3 Dec 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 7 Nov 2025 | Wedbush | Maintains | Outperform | — |
| 29 Sept 2025 | JP Morgan | Maintains | Overweight | — |
| 18 Sept 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 15 Sept 2025 | Guggenheim | Maintains | Buy | — |
| 12 Sept 2025 | BTIG | Maintains | Buy | — |
| 12 Sept 2025 | HC Wainwright & Co. | Maintains | Buy | — |
| 11 Sept 2025 | BTIG | Maintains | Buy | — |
| 2 Sept 2025 | BTIG | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
MAZE analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Maze Therapeutics, Inc. (MAZE) financial data
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- 189.5×
- Price / sales
- 74.5×
- Price / book
- 3.9×
- EV / EBITDA
- −9.1×
Cheaper than 4% of US stocks
Cheaper than 4% of US stocks
Cheaper than 27% of US stocks
Cheaper than 84% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- —
- Operating margin
- −132.8%
- Net margin
- 0.0%
Higher than 13% of US stocks
Higher than 30% of US stocks
- Return on equity
- −38.7%
- Return on assets
- −22.3%
- Dividend yield
- —
Higher than 24% of US stocks
Higher than 18% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
MAZE vs competitors
The nearest names by industry and size, scored by the same model — like for like.
This page is one stock. Monday covers all of them.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. MAZE appears on the weeks it earns a place.
Frequently asked questions about MAZE stock
What is the MAZE stock price forecast for 2026-2027?
The 12 Wall Street analysts covering Maze Therapeutics, Inc. have a median 12-month price target of $55, with estimates ranging from $46 to $110. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is MAZE stock a buy right now?
Of the 12 analysts covering Maze Therapeutics, Inc., 12 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Maze Therapeutics, Inc. 24 out of 100 across roughly 4,600 US stocks as at 1 Aug 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank MAZE?
As at 1 Aug 2026, Maze Therapeutics, Inc. ranks 24 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (77 of 100).
Will MAZE stock go up?
No one can know that. What the data says: the median 12-month target from 12 analysts implies +101.2% from the last close, and Ticker Nerd's factor model ranks Maze Therapeutics, Inc. 24 out of 100 as at 1 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the MAZE stock forecast for 2030?
No analyst covering Maze Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MAZE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $46 to $110 over the next 12 months.
How has MAZE stock performed over the past year?
Maze Therapeutics, Inc. returned +83.4% over the 12 months to 3 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Maze Therapeutics, Inc. do?
Maze Therapeutics Inc. is a clinical-stage biopharmaceutical company developing small molecule precision medicines for renal, cardiovascular, related metabolic diseases, and obesity.
About Maze Therapeutics, Inc.
Maze Therapeutics Inc. is a clinical-stage biopharmaceutical company developing small molecule precision medicines for renal, cardiovascular, related metabolic diseases, and obesity. The company harnesses human genetics through its Compass platform to identify genetic variants in diseases and link them to biological pathways driving conditions in specific patient populations, a process called variant functionalization. Its lead program, MZE829, is an oral small molecule inhibitor of apolipoprotein L1 (APOL1) in phase II clinical trials for APOL1 kidney disease. MZE782, another oral small molecule inhibitor targeting the solute transporter SLC6A19, is in phase I clinical trials for chronic kidney disease and phenylketonuria. Maze Therapeutics Inc. also advances MZE001 for Pompe disease. Focused on novel precision medicine approaches, it addresses unmet needs in kidney and metabolic disorders. Founded in 2017 and headquartered in South San Francisco, California, Maze Therapeutics Inc. plays a key role in advancing genetically informed therapies in the biopharmaceutical sector.
CEO Dr. Jason V. Coloma M.B.A., M.P.H., Ph.D. · 141 employees · United States · https://www.mazetx.com